How Safe are Safe Harbor Regulations?

The phrase “no more rebates” and recent guidance from the Department of Health and ...

Drug Pricing Regulatory Action Near Certain

It is never a good sign when reputational polls show that your industry ranks ...

Hub Services Offer Big Benefits for Retail Launch Brands

Along with their specialty brand counterparts, retail brands are starting to experience the pain ...

Dealing with Insurers’ Copay Accumulators

Over the past couple of years, more and more insurers have started to implement ...

The Scrutiny on Rebates and Prices Will Change the Pharma-Payer Relationship

The government is the largest payer in the U.S. through Medicare and Medicaid, and ...

Four Key Questions About Payer Strategies in 2019

PM360 asked those with expertise in payer strategies how changes are impacting pharma’s relationship ...

Healthcare’s Financial Literacy Gap

A 2016 Harris Poll survey offered this shocking insight: The number of people who ...

Engagement Strategy with IHS & IDNs

Clinical pathways are formalized processes of care designed to reduce treatment variability. They can ...

Psoriasis Treatment: Unmet Needs Present 2019 Opportunities

Psoriasis and related conditions represent as an evolving treatment domain for many pharmas—and obvious ...

Learning to Speak HEOR

As one formulary decision-maker told us: “Recent regulation guidance on FDAMA114 frees up pharma ...